Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis
BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7...
Gespeichert in:
| Veröffentlicht in: | Archives of dermatology (1960) 1998-10, Vol.134 (10), p.1275-1278 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1278 |
|---|---|
| container_issue | 10 |
| container_start_page | 1275 |
| container_title | Archives of dermatology (1960) |
| container_volume | 134 |
| creator | Helmbold, Peter Hegemann, Bernd Holzhausen, Hans-Jürgen Klapperstück, Thomas Marsch, Wolfgang Ch |
| description | BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabling ulcers in intertriginous areas. He had previously been treated with 2 different regimens of antitumoral chemotherapy; one had to be discontinued due to myelosuppression and the other had proved ineffective. We treated with oral etoposide monotherapy at 50 mg/d (22 mg/m2 per day) for 21 days. The treatment was repeated at 28-day intervals for a total of 6 cycles. A rapid initial response with subtotal diminution of the involved skin area was found. No adverse effects were observed. The clinical picture has remained stable during the 7 months following cessation of therapy. CONCLUSION Low-dose oral etoposide treatment is an adequate therapeutic measure for prolonged disease control in adult-type Langerhans cell histiocytosis.--> |
| doi_str_mv | 10.1001/archderm.134.10.1275 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70032789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>189448</ama_id><sourcerecordid>70032789</sourcerecordid><originalsourceid>FETCH-LOGICAL-a349t-df00be12d4de957913cc9aa3ee1ccec5b2da6b6781358bcff97a077a5fcfbd73</originalsourceid><addsrcrecordid>eNpFkD1PwzAQhi0EKqXwA5BAyoDYUvyRxPZYlUJBRV06sEUX26FBSRzsVKj_HpeWMp1097x39oPQDcFjgjF5AKfW2rhmTFgy3jUpT0_QkKRMxCxL6SkaYoxZLAV_P0cX3n-GFBWCDtBACkwykQzR68J-x4_Wm2jpoI5mve2sr7SJ3mxr-7Vx0G2jqo0melP30QLaD-PW0Ppoauo6mle-r6za9iHjL9FZCbU3V4c6Qqun2Wo6jxfL55fpZBEDS2Qf6xLjwhCqE21kyiVhSkkAZgxRyqi0oBqyIuOCsFQUqiwlB8w5pKUqC83ZCN3v13bOfm2M7_Om8iq8BlpjNz7n4c-UCxnAZA8qZ713psw7VzXgtjnB-c5g_mcwDwZ_m8FgiN0e9m-Kxuhj6KAszO8Oc_AK6tJBqyp_xGhCpUhpwK73GDTwf1jIJBHsB73GhQ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70032789</pqid></control><display><type>article</type><title>Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Helmbold, Peter ; Hegemann, Bernd ; Holzhausen, Hans-Jürgen ; Klapperstück, Thomas ; Marsch, Wolfgang Ch</creator><creatorcontrib>Helmbold, Peter ; Hegemann, Bernd ; Holzhausen, Hans-Jürgen ; Klapperstück, Thomas ; Marsch, Wolfgang Ch</creatorcontrib><description>BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabling ulcers in intertriginous areas. He had previously been treated with 2 different regimens of antitumoral chemotherapy; one had to be discontinued due to myelosuppression and the other had proved ineffective. We treated with oral etoposide monotherapy at 50 mg/d (22 mg/m2 per day) for 21 days. The treatment was repeated at 28-day intervals for a total of 6 cycles. A rapid initial response with subtotal diminution of the involved skin area was found. No adverse effects were observed. The clinical picture has remained stable during the 7 months following cessation of therapy. CONCLUSION Low-dose oral etoposide treatment is an adequate therapeutic measure for prolonged disease control in adult-type Langerhans cell histiocytosis.--></description><identifier>ISSN: 0003-987X</identifier><identifier>EISSN: 1538-3652</identifier><identifier>DOI: 10.1001/archderm.134.10.1275</identifier><identifier>PMID: 9801684</identifier><identifier>CODEN: ARDEAC</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Administration, Oral ; Adult ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Drug Administration Schedule ; Etoposide - administration & dosage ; Etoposide - therapeutic use ; Hematologic and hematopoietic diseases ; Histiocytosis, Langerhans-Cell - drug therapy ; Histiocytosis, Langerhans-Cell - pathology ; Humans ; Male ; Medical sciences ; Other diseases. Hematologic involvement in other diseases ; Pharmacology. Drug treatments ; Skin, nail, hair, dermoskeleton</subject><ispartof>Archives of dermatology (1960), 1998-10, Vol.134 (10), p.1275-1278</ispartof><rights>1998 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a349t-df00be12d4de957913cc9aa3ee1ccec5b2da6b6781358bcff97a077a5fcfbd73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamadermatology/articlepdf/10.1001/archderm.134.10.1275$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/archderm.134.10.1275$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76231,76234</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2429852$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9801684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helmbold, Peter</creatorcontrib><creatorcontrib>Hegemann, Bernd</creatorcontrib><creatorcontrib>Holzhausen, Hans-Jürgen</creatorcontrib><creatorcontrib>Klapperstück, Thomas</creatorcontrib><creatorcontrib>Marsch, Wolfgang Ch</creatorcontrib><title>Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis</title><title>Archives of dermatology (1960)</title><addtitle>Arch Dermatol</addtitle><description>BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabling ulcers in intertriginous areas. He had previously been treated with 2 different regimens of antitumoral chemotherapy; one had to be discontinued due to myelosuppression and the other had proved ineffective. We treated with oral etoposide monotherapy at 50 mg/d (22 mg/m2 per day) for 21 days. The treatment was repeated at 28-day intervals for a total of 6 cycles. A rapid initial response with subtotal diminution of the involved skin area was found. No adverse effects were observed. The clinical picture has remained stable during the 7 months following cessation of therapy. CONCLUSION Low-dose oral etoposide treatment is an adequate therapeutic measure for prolonged disease control in adult-type Langerhans cell histiocytosis.--></description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Drug Administration Schedule</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Histiocytosis, Langerhans-Cell - drug therapy</subject><subject>Histiocytosis, Langerhans-Cell - pathology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Other diseases. Hematologic involvement in other diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Skin, nail, hair, dermoskeleton</subject><issn>0003-987X</issn><issn>1538-3652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkD1PwzAQhi0EKqXwA5BAyoDYUvyRxPZYlUJBRV06sEUX26FBSRzsVKj_HpeWMp1097x39oPQDcFjgjF5AKfW2rhmTFgy3jUpT0_QkKRMxCxL6SkaYoxZLAV_P0cX3n-GFBWCDtBACkwykQzR68J-x4_Wm2jpoI5mve2sr7SJ3mxr-7Vx0G2jqo0melP30QLaD-PW0Ppoauo6mle-r6za9iHjL9FZCbU3V4c6Qqun2Wo6jxfL55fpZBEDS2Qf6xLjwhCqE21kyiVhSkkAZgxRyqi0oBqyIuOCsFQUqiwlB8w5pKUqC83ZCN3v13bOfm2M7_Om8iq8BlpjNz7n4c-UCxnAZA8qZ713psw7VzXgtjnB-c5g_mcwDwZ_m8FgiN0e9m-Kxuhj6KAszO8Oc_AK6tJBqyp_xGhCpUhpwK73GDTwf1jIJBHsB73GhQ4</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Helmbold, Peter</creator><creator>Hegemann, Bernd</creator><creator>Holzhausen, Hans-Jürgen</creator><creator>Klapperstück, Thomas</creator><creator>Marsch, Wolfgang Ch</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis</title><author>Helmbold, Peter ; Hegemann, Bernd ; Holzhausen, Hans-Jürgen ; Klapperstück, Thomas ; Marsch, Wolfgang Ch</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a349t-df00be12d4de957913cc9aa3ee1ccec5b2da6b6781358bcff97a077a5fcfbd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Drug Administration Schedule</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Histiocytosis, Langerhans-Cell - drug therapy</topic><topic>Histiocytosis, Langerhans-Cell - pathology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Other diseases. Hematologic involvement in other diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Skin, nail, hair, dermoskeleton</topic><toplevel>online_resources</toplevel><creatorcontrib>Helmbold, Peter</creatorcontrib><creatorcontrib>Hegemann, Bernd</creatorcontrib><creatorcontrib>Holzhausen, Hans-Jürgen</creatorcontrib><creatorcontrib>Klapperstück, Thomas</creatorcontrib><creatorcontrib>Marsch, Wolfgang Ch</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of dermatology (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helmbold, Peter</au><au>Hegemann, Bernd</au><au>Holzhausen, Hans-Jürgen</au><au>Klapperstück, Thomas</au><au>Marsch, Wolfgang Ch</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis</atitle><jtitle>Archives of dermatology (1960)</jtitle><addtitle>Arch Dermatol</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>134</volume><issue>10</issue><spage>1275</spage><epage>1278</epage><pages>1275-1278</pages><issn>0003-987X</issn><eissn>1538-3652</eissn><coden>ARDEAC</coden><abstract>BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabling ulcers in intertriginous areas. He had previously been treated with 2 different regimens of antitumoral chemotherapy; one had to be discontinued due to myelosuppression and the other had proved ineffective. We treated with oral etoposide monotherapy at 50 mg/d (22 mg/m2 per day) for 21 days. The treatment was repeated at 28-day intervals for a total of 6 cycles. A rapid initial response with subtotal diminution of the involved skin area was found. No adverse effects were observed. The clinical picture has remained stable during the 7 months following cessation of therapy. CONCLUSION Low-dose oral etoposide treatment is an adequate therapeutic measure for prolonged disease control in adult-type Langerhans cell histiocytosis.--></abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>9801684</pmid><doi>10.1001/archderm.134.10.1275</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-987X |
| ispartof | Archives of dermatology (1960), 1998-10, Vol.134 (10), p.1275-1278 |
| issn | 0003-987X 1538-3652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70032789 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Administration, Oral Adult Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Chronic Disease Drug Administration Schedule Etoposide - administration & dosage Etoposide - therapeutic use Hematologic and hematopoietic diseases Histiocytosis, Langerhans-Cell - drug therapy Histiocytosis, Langerhans-Cell - pathology Humans Male Medical sciences Other diseases. Hematologic involvement in other diseases Pharmacology. Drug treatments Skin, nail, hair, dermoskeleton |
| title | Low-Dose Oral Etoposide Monotherapy in Adult Langerhans Cell Histiocytosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-Dose%20Oral%20Etoposide%20Monotherapy%20in%20Adult%20Langerhans%20Cell%20Histiocytosis&rft.jtitle=Archives%20of%20dermatology%20(1960)&rft.au=Helmbold,%20Peter&rft.date=1998-10-01&rft.volume=134&rft.issue=10&rft.spage=1275&rft.epage=1278&rft.pages=1275-1278&rft.issn=0003-987X&rft.eissn=1538-3652&rft.coden=ARDEAC&rft_id=info:doi/10.1001/archderm.134.10.1275&rft_dat=%3Cproquest_cross%3E70032789%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70032789&rft_id=info:pmid/9801684&rft_ama_id=189448&rfr_iscdi=true |